References
- Frohman EM. Multiple sclerosis. Med Clin North Am 2003;87:867-897, viii-ix.
- Pope GC, Urato CJ, Kulas ED, Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002;58:37-43.
- Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425.
- Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52.
- Patwardhan MB, Matchar DB, Samsa GP, Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005;11:232-239.
- Goodin DS, Frohman EM, Garmany GP, Jr., Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
- Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981;33:11-24.
- Stuart WH. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management. J Manag Care Pharm 2004;10:S19-25.
- Rich SR, Coleman IC, Cook R, Stepped-care approach to treating MS: a managed care treatment algorithm. J Manag Care Pharm 2004;10:S26-32.
- Rio J, Nos C, Tintore M, Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352.
- Coyle PK. Switching algorithms: from one immunomodulatory agent to another. J Neurol 2008;255(Suppl 1):44-50.
- Zaffaroni M. Treatment optimisation in multiple sclerosis. Neurol Sci 2005;26(Suppl 4):S187-192.
- Rio J, Nos C, Tintore M, Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002;52:400-406.
- Clerico M, Barbero P, Contessa G, Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007;259:104-108.
- Twork S, Nippert I, Scherer P, Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin 2007;23:1209-1215.
- Tremlett H, Van der Mei I, Pittas F, Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008;17:565-576.
- Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-554.
- Rio J, Porcel J, Tellez N, Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-309.
- O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50.